Aytu BioPharma, Inc. (AYTU)
USD 1.34
(-7.59%)
USD 1.34
(-7.59%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.38 Million | -5.12 Million | -28.82 Million | -25.96 Million | -28.37 Million | -13.83 Million |
| Net Income | -15.84 Million | -17.05 Million | -110.17 Million | -58.28 Million | -13.62 Million | -27.13 Million |
| Depreciation & Amortization | 8.27 Million | 8.81 Million | 10.25 Million | 9.2 Million | 6.24 Million | 2.72 Million |
| Deferred income taxes | - | 3.26 Million | - | 22.33 Million | 573.52 Thousand | -80.77 Thousand |
| Stock-based compensation | 2.91 Million | 6.04 Million | 5.24 Million | 3.57 Million | 1.07 Million | 1.02 Million |
| Change in working capital | -4.66 Million | -5.79 Million | -10.86 Million | 1.68 Million | -12.6 Million | -210.19 Thousand |
| Other non-cash items | 1.25 Million | -404 Thousand | 76.71 Million | -4.46 Million | -10.04 Million | 9.84 Million |
| Investing Cash Flow | -329 Thousand | -117 Thousand | -3.24 Million | -2.78 Million | -5.65 Million | -1.06 Million |
| Investments in PPE | - | - | - | -2.34 Million | - | -59.84 Thousand |
| Acquisitions | - | -5000.00 | -3.17 Million | -2.82 Million | 188.22 Thousand | -505.02 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -329 Thousand | -112 Thousand | -70 Thousand | 2.38 Million | -5.84 Million | -497.11 Thousand |
| Financing Cash Flow | -1.26 Million | 8.87 Million | 1.53 Million | 30.31 Million | 71.06 Million | 19.07 Million |
| Debt repayment | -1.89 Million | -2.34 Million | -172.45 Million | -968 Thousand | -19.43 Million | -5 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.46 Million | 15.57 Million | 11.69 Million | 40.14 Million | 48.08 Thousand | 11.69 Thousand |
| Other Financing Activities | -2.83 Million | -4.35 Million | 162.29 Million | 31.28 Million | 90.45 Million | 24.06 Million |
| Accounts receivables | 5.32 Million | -7.15 Million | 6.53 Million | 1.54 Million | -3.56 Million | -1.16 Million |
| Accounts payables | -2.87 Million | 2.38 Million | -7.68 Million | -3.24 Million | -1.37 Million | 134.77 Thousand |
| Inventory | -2.9 Million | -3.6 Million | 1.29 Million | 2.78 Million | -6.95 Million | -101.09 Thousand |
| Other working capital | 3.84 Million | 2.58 Million | -11.01 Million | 596 Thousand | -721.89 Thousand | 918.12 Thousand |
| Cash at beginning of period | 22.98 Million | 19.36 Million | 49.9 Million | 48.33 Million | 11.29 Million | 7.11 Million |
| Cash at end of period | 20 Million | 22.98 Million | 19.36 Million | 49.9 Million | 48.33 Million | 11.29 Million |
| Capital Expenditure | - | - | - | -2.34 Million | - | -59.84 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -2.97 Million | 3.62 Million | -30.54 Million | 1.56 Million | 37.03 Million | 4.18 Million |
| Free Cash Flow | -1.38 Million | -5.12 Million | -28.82 Million | -28.3 Million | -28.37 Million | -13.89 Million |
| Breakdown | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.61 Million | -2.88 Million | -220 Thousand | -8.12 Million | -17.05 Million | -2.45 Million |
| Depreciation & Amortization | 1.94 Million | 1.8 Million | 2.17 Million | 2.23 Million | 8.81 Million | 2.11 Million |
| Deferred income taxes | - | - | 659 Thousand | -20 Thousand | 3.26 Million | 6.67 Million |
| Stock-based compensation | 352 Thousand | 811 Thousand | 820 Thousand | 930 Thousand | 6.04 Million | 900 Thousand |
| Change in working capital | -42 Thousand | 416 Thousand | -3.68 Million | -1.35 Million | -5.79 Million | 2.45 Million |
| Other non-cash items | 844 Thousand | 4.97 Million | 110 Thousand | 6.12 Million | -404 Thousand | -326 Thousand |
| Investing Cash Flow | -34 Thousand | -45 Thousand | -174 Thousand | -76 Thousand | -117 Thousand | -155 Thousand |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | -5000.00 | -5000.00 |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -34 Thousand | -45 Thousand | -174 Thousand | -76 Thousand | -112 Thousand | -150 Thousand |
| Financing Cash Flow | 1.06 Million | 530 Thousand | -126 Thousand | -2.73 Million | 8.87 Million | -5.4 Million |
| Debt repayment | -1.83 Million | -530 Thousand | -23 Thousand | -22 Thousand | -2.34 Million | -2.27 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.38 Million | - | 86 Thousand | -160 Thousand | 15.57 Million | 2.56 Million |
| Other Financing Activities | -475 Thousand | 555 Thousand | -189 Thousand | -2.55 Million | -4.35 Million | -5.69 Million |
| Accounts receivables | 6.3 Million | -522 Thousand | 479 Thousand | -945 Thousand | -7.15 Million | 5.18 Million |
| Accounts payables | 58 Thousand | 95 Thousand | -3.94 Million | 914 Thousand | 2.38 Million | -1.33 Million |
| Inventory | -1.23 Million | -534 Thousand | -117 Thousand | -1.02 Million | -3.6 Million | -622 Thousand |
| Other working capital | -45 Thousand | 1.37 Million | -99 Thousand | -297 Thousand | 2.58 Million | -765 Thousand |
| Cash at beginning of period | 19.76 Million | 19.52 Million | 19.96 Million | 22.98 Million | 19.36 Million | 19.17 Million |
| Cash at end of period | 20 Million | 19.76 Million | 19.52 Million | 19.96 Million | 22.98 Million | 22.98 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 246 Thousand | 231 Thousand | -435 Thousand | -3.02 Million | 3.62 Million | 3.8 Million |
| Free Cash Flow | -788 Thousand | -254 Thousand | -135 Thousand | -211 Thousand | -5.12 Million | 9.36 Million |
8413
SNOTF
SUBCY
AJX
CRTD
AVCN